Clinical Trial Update: Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update comparing the Titanium-nitride-oxide coated bio-active stent (Optimax) to the everolimus-eluting Synergy stent in acute coronary s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• Optimax TiNO-coated Bio-Active-Stent (Titanium-nitride-oxide coated bio-active stent)
• Synergy Everolimus-Eluting Stent (Everolimus-eluting stent)

Snippet

Sponsor: The Hospital District of Satakunta | Conditions: Myocardial Infarction, Percutaneous Coronary Intervention | Phase 4 | Status: UNKNOWN